NFKB1 and Friedreich ataxia: Recently, omaveloxolone, a potent activator of Nrf2 which represents a key mediator of the antioxidant response in FRDA but also a NF-kB-mediated inflammatory response suppressor, a trait with unclear effects on FRDA pathophysiology, was approved by the FDA as the first agent for the therapeutic management of adults and adolescents aged 16 years and older with FRDA [7, 8].